Co-precipitation Molecules Hemopexin and Transferrin May Be Key Molecules for Fibrillogenesis in TTR V30M Amyloidogenesis

Overview

Journal Transgenic Res

Specialty Molecular Biology

Date 2017 Dec 31

PMID 29288430

Citations 5

Authors

Mika Ohta

Aki Sugano

Naoya Hatano

Hirotaka Sato

Hirofumi Shimada

Hitoshi Niwa

Toshiyuki Sakaeda

Hajime Tei

Yoshiyuki Sakaki

Ken-Ichi Yamamura

Yutaka Takaoka

Affiliations

Soon will be listed here.

Abstract

The disease model of familial amyloidotic polyneuropathy-7.2-hMet30 mice-manifests amyloid deposition that consists of a human amyloidogenic mutant transthyretin (TTR) (TTR V30M). Our previous study found amyloid deposits in 14 of 27 7.2-hMet30 mice at 21-24 months of age. In addition, non-fibrillar TTR deposits were found in amyloid-negative 7.2hMet30 mice. These results suggested that TTR amyloidogenesis required not only mutant TTR but also an additional factor (or factors) as an etiologic molecule. To determine the differences in serum proteome in amyloid-positive and amyloid-negative mice in the 7.2-hMet30 model, we used proteomic analyses and studied serum samples obtained from these mice. Hemopexin (HPX) and transferrin (Tf) were detected in the serum samples from amyloid-positive mice and were also found in amyloid deposits via immunohistochemistry, but serum samples from amyloid-negative mice did not contain HPX and Tf. These two proteins were also not detected in non-fibrillar TTR deposits. In addition, in silico analyses suggested that HPX and Tf facilitate destabilization of TTR secondary structures and misfolding of TTR. These results suggest that HPX and Tf may be associated with TTR amyloidogenesis after fibrillogenesis in vivo.

Citing Articles

Targeted sequencing of selected functional genes in patients with wild-type transthyretin amyloidosis.

Moreno-Gazquez I, Perez-Palacios R, Abengochea-Quilez L, Lahuerta Pueyo C, Roteta Unceta Barrenechea A, Andres Gracia A BMC Res Notes. 2023; 16(1):249.

PMID: 37784196 PMC: 10546623. DOI: 10.1186/s13104-023-06491-z.

Prediction of infectivity of SARS-CoV2: Mathematical model with analysis of docking simulation for spike proteins and angiotensin-converting enzyme 2.

Takaoka Y, Sugano A, Morinaga Y, Ohta M, Miura K, Kataguchi H Microb Risk Anal. 2022; 22:100227.

PMID: 35756961 PMC: 9212987. DOI: 10.1016/j.mran.2022.100227.

Genotype-Phenotype Correlation in Exon 8 to 9 Missense Variants.

Nagano C, Takaoka Y, Kamei K, Hamada R, Ichikawa D, Tanaka K Kidney Int Rep. 2021; 6(8):2114-2121.

PMID: 34386660 PMC: 8343804. DOI: 10.1016/j.ekir.2021.05.009.

Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic Amyloid Disease.

Giadone R, Liberti D, Matte T, Rosarda J, Torres-Arancivia C, Ghosh S Stem Cell Reports. 2020; 15(2):515-528.

PMID: 32735824 PMC: 7419739. DOI: 10.1016/j.stemcr.2020.07.003.

Establishment of the experimental procedure for prediction of conjugation capacity in mutant UGT1A1.

Takaoka Y, Takeuchi A, Sugano A, Miura K, Ohta M, Suzuki T PLoS One. 2019; 14(11):e0225244.

PMID: 31730632 PMC: 6857941. DOI: 10.1371/journal.pone.0225244.

References

Takaoka Y, Ohta M, Miyakawa K, Nakamura O, Suzuki M, Takahashi K . Cysteine 10 is a key residue in amyloidogenesis of human transthyretin Val30Met. Am J Pathol. 2003; 164(1):337-45. PMC: 1602210. DOI: 10.1016/s0002-9440(10)63123-9. View

Pieper U, Webb B, Barkan D, Schneidman-Duhovny D, Schlessinger A, Braberg H . ModBase, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res. 2010; 39(Database issue):D465-74. PMC: 3013688. DOI: 10.1093/nar/gkq1091. View

Lai Z, Colon W, Kelly J . The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry. 1996; 35(20):6470-82. DOI: 10.1021/bi952501g. View

Chen R, Li L, Weng Z . ZDOCK: an initial-stage protein-docking algorithm. Proteins. 2003; 52(1):80-7. DOI: 10.1002/prot.10389. View

Glenner G . Amyloid deposits and amyloidosis: the beta-fibrilloses (second of two parts). N Engl J Med. 1980; 302(24):1333-43. DOI: 10.1056/NEJM198006123022403. View

Yi S, Takahashi K, Naito M, Tashiro F, Wakasugi S, Maeda S . Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met30) gene. Pathologic similarity to human familial amyloidotic polyneuropathy, type I. Am J Pathol. 1991; 138(2):403-12. PMC: 1886191. View

Nakano E, Ono R, Masaki T, Takeuchi S, Takaoka Y, Maeda E . Differences in clinical phenotype among patients with XP complementation group D: 3D structure and ATP-docking of XPD in silico. J Invest Dermatol. 2014; 134(6):1775-1778. DOI: 10.1038/jid.2014.14. View

Yamamura K, Wakasugi S, Maeda S, INOMOTO T, Iwanaga T, Uehira M . Tissue-specific and developmental expression of human transthyretin gene in transgenic mice. Dev Genet. 1987; 8(4):195-205. DOI: 10.1002/dvg.1020080404. View

Sakaki Y, Yoshioka K, Tanahashi H, Furuya H, Sasaki H . Human transthyretin (prealbumin) gene and molecular genetics of familial amyloidotic polyneuropathy. Mol Biol Med. 1989; 6(2):161-8. View

10.

Touw W, Baakman C, Black J, Te Beek T, Krieger E, Joosten R . A series of PDB-related databanks for everyday needs. Nucleic Acids Res. 2014; 43(Database issue):D364-8. PMC: 4383885. DOI: 10.1093/nar/gku1028. View

11.

Mu Y, Jin S, Shen J, Sugano A, Takaoka Y, Qiang L . CHF5074 (CSP-1103) stabilizes human transthyretin in mice humanized at the transthyretin and retinol-binding protein loci. FEBS Lett. 2015; 589(7):849-56. DOI: 10.1016/j.febslet.2015.02.020. View

12.

Nagata Y, Tashiro F, Yi S, Murakami T, Maeda S, Takahashi K . A 6-kb upstream region of the human transthyretin gene can direct developmental, tissue-specific, and quantitatively normal expression in transgenic mouse. J Biochem. 1995; 117(1):169-75. DOI: 10.1093/oxfordjournals.jbchem.a124705. View

13.

Kelly J . The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol. 1998; 8(1):101-6. DOI: 10.1016/s0959-440x(98)80016-x. View

14.

Yang M, Lei M, Huo S . Why is Leu55-->Pro55 transthyretin variant the most amyloidogenic: insights from molecular dynamics simulations of transthyretin monomers. Protein Sci. 2003; 12(6):1222-31. PMC: 2323890. DOI: 10.1110/ps.0239703. View

15.

Nagai H, Takaoka Y, Sugano A, Nakamachi Y, Kawano S, Nishigori C . Identification of a heterozygous p.Gly568Val missense mutation in the TRPV3 gene in a Japanese patient with Olmsted syndrome: In silico analysis of TRPV3. J Dermatol. 2017; 44(9):1059-1062. DOI: 10.1111/1346-8138.13844. View

16.

Ogasawara M, Nakamura Y, Morikawa N, Nitanai H, Moriguchi S, Chiba R . Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor. Cancer Chemother Pharmacol. 2016; 77(5):1019-29. DOI: 10.1007/s00280-016-3021-y. View

17.

Colon W, Kelly J . Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry. 1992; 31(36):8654-60. DOI: 10.1021/bi00151a036. View

18.

Lei M, Yang M, Huo S . Intrinsic versus mutation dependent instability/flexibility: a comparative analysis of the structure and dynamics of wild-type transthyretin and its pathogenic variants. J Struct Biol. 2004; 148(2):153-68. DOI: 10.1016/j.jsb.2004.06.007. View

19.

Bourgault S, Solomon J, Reixach N, Kelly J . Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion. Biochemistry. 2011; 50(6):1001-15. PMC: 3035766. DOI: 10.1021/bi101822y. View

20.

Qiang L, Guan Y, Li X, Liu L, Mu Y, Sugano A . CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects. Amyloid. 2017; 24(1):42-51. DOI: 10.1080/13506129.2017.1308348. View